Eosinophilic fasciitis and eosinophilic colitis: a rare association.

1. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon with an anti-CD20. Blood 2003; 101:3818–26. 2. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827–34. 3. Rosenthal E, Pesce A, Karsenti JM, Allieri-Rosenthal MA, Cassuto JP. Polyneuropathy and vasculitis associated with IgG type I cryoglobulinemia can be treated effectively with the anti-CD20 monoclonal antibody (rituximab). Blood 2001;98 (Suppl.):292b. 4. Brouet JC, Clauvel JP, Danon E, Klein M, Serligman M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775–88. 5. Engelhardt M, Jakob A, Rüter B, Trepel M, Hirsch F, Lübbert M. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood 2002;100:1922–3. 6. Gertz MA, Anagnostopoulos A, Anderson K et al. Treatment recommendations in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia. Semin Oncol 2003;30:121–6. 7. Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949–54. 8. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders. Arthritis Rheum 2003;48:1484–92. 9. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2003;98: 952–7. 10. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc RIIIa gene. Blood 2002;99:754–8.